Paris, France-based EOSimaging has acquired the worldwide rights to scoliosis progression prognosis software technology.
The software’s algorithm uses 3D and 2D clinical parameters obtained from EOSsystems to establish a predictive score indicating a patient’s risk of progressing from an early stage of scoliosis to a severe form of the disease.
The EOS platform provides 2D and 3D full-body, stereoradiographic images of patients in functional positions.
A clinical study of the technology has been launched in centers in the U.S., Canada, France, Japan, Singapore and Hong Kong. — Michael Cipriano